The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Non-Insulin Therapies for Diabetes Market Research Report 2025

Global Non-Insulin Therapies for Diabetes Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1978738

No of Pages : 104

Ask Your Query
Synopsis
The global Non-Insulin Therapies for Diabetes market was valued at US$ 31940 million in 2023 and is anticipated to reach US$ 59820 million by 2030, witnessing a CAGR of 8.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Insulin Therapies for Diabetes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Insulin Therapies for Diabetes.
Report Scope
The Non-Insulin Therapies for Diabetes market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Insulin Therapies for Diabetes market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Insulin Therapies for Diabetes companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Segment by Type
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Segment by Application
Monitoring
Diagnosis
Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Insulin Therapies for Diabetes companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Amylin Agonists
1.2.4 Biguanides
1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.6 Glinides / Meglitinides
1.2.7 GLP-1 Analogs / GLP-1 Agonists
1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.9 Sulfonylureas
1.2.10 Thiazolidinediones
1.2.11 Others
1.3 Market by Application
1.3.1 Global Non-Insulin Therapies for Diabetes Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2019-2030)
2.2 Non-Insulin Therapies for Diabetes Growth Trends by Region
2.2.1 Global Non-Insulin Therapies for Diabetes Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Size by Region (2019-2024)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2025-2030)
2.3 Non-Insulin Therapies for Diabetes Market Dynamics
2.3.1 Non-Insulin Therapies for Diabetes Industry Trends
2.3.2 Non-Insulin Therapies for Diabetes Market Drivers
2.3.3 Non-Insulin Therapies for Diabetes Market Challenges
2.3.4 Non-Insulin Therapies for Diabetes Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2019-2024)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2019-2024)
3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2023
3.5 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
3.6 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
3.7 Date of Enter into Non-Insulin Therapies for Diabetes Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Insulin Therapies for Diabetes Breakdown Data by Type
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2019-2024)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2025-2030)
5 Non-Insulin Therapies for Diabetes Breakdown Data by Application
5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2019-2024)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2019-2030)
6.2 North America Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2019-2030)
7.2 Europe Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2019-2030)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2019-2030)
9.2 Latin America Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024)
9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2019-2030)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.2.5 Eli Lilly Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Detail
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Intarcia Therapeutics
11.4.1 Intarcia Therapeutics Company Detail
11.4.2 Intarcia Therapeutics Business Overview
11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.4.5 Intarcia Therapeutics Recent Development
11.5 Servier
11.5.1 Servier Company Detail
11.5.2 Servier Business Overview
11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.5.5 Servier Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Dong-A Pharmaceutical
11.8.1 Dong-A Pharmaceutical Company Detail
11.8.2 Dong-A Pharmaceutical Business Overview
11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.8.5 Dong-A Pharmaceutical Recent Development
11.9 Luye Pharma Group
11.9.1 Luye Pharma Group Company Detail
11.9.2 Luye Pharma Group Business Overview
11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.9.5 Luye Pharma Group Recent Development
11.10 Eurofarma
11.10.1 Eurofarma Company Detail
11.10.2 Eurofarma Business Overview
11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.10.5 Eurofarma Recent Development
11.11 Geropharm
11.11.1 Geropharm Company Detail
11.11.2 Geropharm Business Overview
11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.11.5 Geropharm Recent Development
11.12 Alkem Labs
11.12.1 Alkem Labs Company Detail
11.12.2 Alkem Labs Business Overview
11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.12.5 Alkem Labs Recent Development
11.13 SatRx
11.13.1 SatRx Company Detail
11.13.2 SatRx Business Overview
11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.13.5 SatRx Recent Development
11.14 Jiangsu Hansoh Pharmaceutical
11.14.1 Jiangsu Hansoh Pharmaceutical Company Detail
11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.14.5 Jiangsu Hansoh Pharmaceutical Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Detail
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.15.5 Novo Nordisk Recent Development
11.16 Emisphere
11.16.1 Emisphere Company Detail
11.16.2 Emisphere Business Overview
11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.16.5 Emisphere Recent Development
11.17 Uni-Bio Science Group
11.17.1 Uni-Bio Science Group Company Detail
11.17.2 Uni-Bio Science Group Business Overview
11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.17.5 Uni-Bio Science Group Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.18.5 Takeda Recent Development
11.19 3SBio
11.19.1 3SBio Company Detail
11.19.2 3SBio Business Overview
11.19.3 3SBio Non-Insulin Therapies for Diabetes Introduction
11.19.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.19.5 3SBio Recent Development
11.20 Jiangsu Hengrui Medicine
11.20.1 Jiangsu Hengrui Medicine Company Detail
11.20.2 Jiangsu Hengrui Medicine Business Overview
11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024)
11.20.5 Jiangsu Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Alpha-glucosidase Inhibitors
Table 3. Key Players of Amylin Agonists
Table 4. Key Players of Biguanides
Table 5. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Table 6. Key Players of Glinides / Meglitinides
Table 7. Key Players of GLP-1 Analogs / GLP-1 Agonists
Table 8. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Table 9. Key Players of Sulfonylureas
Table 10. Key Players of Thiazolidinediones
Table 11. Key Players of Others
Table 12. Global Non-Insulin Therapies for Diabetes Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Non-Insulin Therapies for Diabetes Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Non-Insulin Therapies for Diabetes Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Non-Insulin Therapies for Diabetes Market Share by Region (2019-2024)
Table 16. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Non-Insulin Therapies for Diabetes Market Share by Region (2025-2030)
Table 18. Non-Insulin Therapies for Diabetes Market Trends
Table 19. Non-Insulin Therapies for Diabetes Market Drivers
Table 20. Non-Insulin Therapies for Diabetes Market Challenges
Table 21. Non-Insulin Therapies for Diabetes Market Restraints
Table 22. Global Non-Insulin Therapies for Diabetes Revenue by Players (2019-2024) & (US$ Million)
Table 23. Global Non-Insulin Therapies for Diabetes Market Share by Players (2019-2024)
Table 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2023)
Table 25. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue (US$ Million) in 2023
Table 26. Global 5 Largest Players Market Share by Non-Insulin Therapies for Diabetes Revenue (CR5 and HHI) & (2019-2024)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
Table 29. Date of Enter into Non-Insulin Therapies for Diabetes Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Non-Insulin Therapies for Diabetes Market Size by Type (2019-2024) & (US$ Million)
Table 32. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2019-2024)
Table 33. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 34. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2025-2030)
Table 35. Global Non-Insulin Therapies for Diabetes Market Size by Application (2019-2024) & (US$ Million)
Table 36. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2019-2024)
Table 37. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 38. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2025-2030)
Table 39. North America Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. North America Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024) & (US$ Million)
Table 41. North America Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030) & (US$ Million)
Table 42. Europe Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030) & (US$ Million)
Table 45. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 46. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2019-2024) & (US$ Million)
Table 47. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2025-2030) & (US$ Million)
Table 48. Latin America Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024) & (US$ Million)
Table 50. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030) & (US$ Million)
Table 51. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 52. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2019-2024) & (US$ Million)
Table 53. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2025-2030) & (US$ Million)
Table 54. GSK Company Detail
Table 55. GSK Business Overview
Table 56. GSK Non-Insulin Therapies for Diabetes Product
Table 57. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 58. GSK Recent Development
Table 59. Eli Lilly Company Detail
Table 60. Eli Lilly Business Overview
Table 61. Eli Lilly Non-Insulin Therapies for Diabetes Product
Table 62. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 63. Eli Lilly Recent Development
Table 64. Sumitomo Dainippon Pharma Company Detail
Table 65. Sumitomo Dainippon Pharma Business Overview
Table 66. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product
Table 67. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 68. Sumitomo Dainippon Pharma Recent Development
Table 69. Intarcia Therapeutics Company Detail
Table 70. Intarcia Therapeutics Business Overview
Table 71. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product
Table 72. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 73. Intarcia Therapeutics Recent Development
Table 74. Servier Company Detail
Table 75. Servier Business Overview
Table 76. Servier Non-Insulin Therapies for Diabetes Product
Table 77. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 78. Servier Recent Development
Table 79. Pfizer Company Detail
Table 80. Pfizer Business Overview
Table 81. Pfizer Non-Insulin Therapies for Diabetes Product
Table 82. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Merck Company Detail
Table 85. Merck Business Overview
Table 86. Merck Non-Insulin Therapies for Diabetes Product
Table 87. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 88. Merck Recent Development
Table 89. Dong-A Pharmaceutical Company Detail
Table 90. Dong-A Pharmaceutical Business Overview
Table 91. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 92. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 93. Dong-A Pharmaceutical Recent Development
Table 94. Luye Pharma Group Company Detail
Table 95. Luye Pharma Group Business Overview
Table 96. Luye Pharma Group Non-Insulin Therapies for Diabetes Product
Table 97. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 98. Luye Pharma Group Recent Development
Table 99. Eurofarma Company Detail
Table 100. Eurofarma Business Overview
Table 101. Eurofarma Non-Insulin Therapies for Diabetes Product
Table 102. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 103. Eurofarma Recent Development
Table 104. Geropharm Company Detail
Table 105. Geropharm Business Overview
Table 106. Geropharm Non-Insulin Therapies for Diabetes Product
Table 107. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 108. Geropharm Recent Development
Table 109. Alkem Labs Company Detail
Table 110. Alkem Labs Business Overview
Table 111. Alkem Labs Non-Insulin Therapies for Diabetes Product
Table 112. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 113. Alkem Labs Recent Development
Table 114. SatRx Company Detail
Table 115. SatRx Business Overview
Table 116. SatRx Non-Insulin Therapies for Diabetes Product
Table 117. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 118. SatRx Recent Development
Table 119. Jiangsu Hansoh Pharmaceutical Company Detail
Table 120. Jiangsu Hansoh Pharmaceutical Business Overview
Table 121. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 122. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 123. Jiangsu Hansoh Pharmaceutical Recent Development
Table 124. Novo Nordisk Company Detail
Table 125. Novo Nordisk Business Overview
Table 126. Novo Nordisk Non-Insulin Therapies for Diabetes Product
Table 127. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 128. Novo Nordisk Recent Development
Table 129. Emisphere Company Detail
Table 130. Emisphere Business Overview
Table 131. Emisphere Non-Insulin Therapies for Diabetes Product
Table 132. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 133. Emisphere Recent Development
Table 134. Uni-Bio Science Group Company Detail
Table 135. Uni-Bio Science Group Business Overview
Table 136. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product
Table 137. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 138. Uni-Bio Science Group Recent Development
Table 139. Takeda Company Detail
Table 140. Takeda Business Overview
Table 141. Takeda Non-Insulin Therapies for Diabetes Product
Table 142. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 143. Takeda Recent Development
Table 144. 3SBio Company Detail
Table 145. 3SBio Business Overview
Table 146. 3SBio Non-Insulin Therapies for Diabetes Product
Table 147. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 148. 3SBio Recent Development
Table 149. Jiangsu Hengrui Medicine Company Detail
Table 150. Jiangsu Hengrui Medicine Business Overview
Table 151. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product
Table 152. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2019-2024) & (US$ Million)
Table 153. Jiangsu Hengrui Medicine Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Insulin Therapies for Diabetes Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2023 VS 2030
Figure 3. Alpha-glucosidase Inhibitors Features
Figure 4. Amylin Agonists Features
Figure 5. Biguanides Features
Figure 6. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features
Figure 7. Glinides / Meglitinides Features
Figure 8. GLP-1 Analogs / GLP-1 Agonists Features
Figure 9. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features
Figure 10. Sulfonylureas Features
Figure 11. Thiazolidinediones Features
Figure 12. Others Features
Figure 13. Global Non-Insulin Therapies for Diabetes Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 14. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2023 VS 2030
Figure 15. Monitoring Case Studies
Figure 16. Diagnosis Case Studies
Figure 17. Treatment Case Studies
Figure 18. Others Case Studies
Figure 19. Non-Insulin Therapies for Diabetes Report Years Considered
Figure 20. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 21. Global Non-Insulin Therapies for Diabetes Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 22. Global Non-Insulin Therapies for Diabetes Market Share by Region: 2023 VS 2030
Figure 23. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2023
Figure 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2023)
Figure 25. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2023
Figure 26. North America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Non-Insulin Therapies for Diabetes Market Share by Country (2019-2030)
Figure 28. United States Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Canada Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Europe Non-Insulin Therapies for Diabetes Market Share by Country (2019-2030)
Figure 32. Germany Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. France Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. U.K. Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Italy Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Russia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Nordic Countries Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Region (2019-2030)
Figure 40. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. South Korea Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Latin America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Latin America Non-Insulin Therapies for Diabetes Market Share by Country (2019-2030)
Figure 48. Mexico Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Brazil Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Country (2019-2030)
Figure 52. Turkey Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. GSK Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 55. Eli Lilly Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 56. Sumitomo Dainippon Pharma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 57. Intarcia Therapeutics Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 58. Servier Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 59. Pfizer Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 60. Merck Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 61. Dong-A Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 62. Luye Pharma Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 63. Eurofarma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 64. Geropharm Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 65. Alkem Labs Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 66. SatRx Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 67. Jiangsu Hansoh Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 68. Novo Nordisk Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 69. Emisphere Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 70. Uni-Bio Science Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 71. Takeda Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 72. 3SBio Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 73. Jiangsu Hengrui Medicine Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2019-2024)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock